Amended Current Report Filing (8-k/a)

Date : 10/24/2018 @ 4:52PM
Source : Edgar (US Regulatory)
Stock : Mount Tam Biotechnologies, Inc. (PC) (MNTM)
Quote : 0.02275  0.00275 (13.75%) @ 9:26PM
Mount TAM Biotechnologies, Inc. share price Chart

Amended Current Report Filing (8-k/a)


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K/A

Amendment No. 1

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

Of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 18, 2018

MOUNT TAM BIOTECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

 

 

 

NEVADA

333-192060

45-3797537

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification Number)

 

7250 Redwood Boulevard, Suite 300

Novato, California  94925

(425) 214-4079

 

(Address, including zip code, and telephone number,

including area code, of registrant’s principal executive offices)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

  Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company   ☐


 

 



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 


 



EXPLANATORY NOTE

 

On October 23, 2018, Mount Tam Biotechnologies, Inc., a Nevada corporation (the “Company”) filed a current report on Form 8-K (the “8-K”) reporting the sale of its wholly-owned subsidiary to ARJ Consulting, LLC, a New York limited liability company. This Amendment No. 1 on Form 8-K/A (this “Amendment”) is being filed to correct a scrivener’s error regarding the date of the earliest event reported. The 8-K indicated the Date of the Report was September 18, 2018; the correct date was October 18, 2018, as indicated on the above cover page.

 

Item 1.01 Entry into a Material Definitive Agreement.  

Item 2.01 Completion of Acquisition or Disposition of Assets.  

 

Sale of Wholly-Owned Subsidiary

 

On October 18, 2018, Mount Tam Biotechnologies, Inc., a Nevada corporation (the “Company”), and its wholly-owned subsidiary, Mount Tam Biotechnologies, Inc., a Delaware corporation (the “Subsidiary”) entered into a stock purchase agreement (the “SPA”) with ARJ Consulting, LLC, a New York limited liability company (the “Buyer”), pursuant to which the Company sold 100% of the capital stock in and of Subsidiary to the Buyer (the “Sale Transaction”). Prior to the Sale Transaction, the Company caused Subsidiary to transfer certain assets and a key license that Subsidiary was holding to another wholly-owned subsidiary of the Company, Mount Tam Therapeutics, Inc., a Delaware corporation. At the time of the Sale Transaction Subsidiary possessed certain Net Operating Losses and tax credits. Pursuant to the terms of the SPA, the Buyer purchased Subsidiary for a purchase price of $410,000.

 

The foregoing description of the sale of Subsidiary does not purport to be complete and is qualified in its entirety by reference to the actual terms and conditions of the SPA, a copy of which is being filed as Exhibit 10.1 hereto, and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

 

Description

10.1

 

Stock Purchase Agreement

 

 

 


 



SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

MOUNT TAM BIOTECHNOLOGIES, INC.

 

 

 

Date:   

October 23, 2018

 

By:

/s/ Richard Marshak

 

Name:

Richard Marshak

 

Title:

Chief Executive Officer

 


 

Mount TAM Biotechnologies, Inc. (OTCBB:MNTM)
Historical Stock Chart

1 Year : From Dec 2017 to Dec 2018

Click Here for more Mount TAM Biotechnologies, Inc. Charts.

Mount TAM Biotechnologies, Inc. (OTCBB:MNTM)
Intraday Stock Chart

Today : Tuesday 11 December 2018

Click Here for more Mount TAM Biotechnologies, Inc. Charts.

Latest MNTM Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20181212 04:51:36